Open access
Open access
Powered by Google Translator Translator

Critical Care

Review: “Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19

7 Feb, 2021 | 21:13h | UTC

“Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19 – Anesthesia

 


SR/MA: Colistin nephrotoxicity

5 Feb, 2021 | 01:21h | UTC

Colistin Nephrotoxicity: Meta-analysis of Randomized Controlled Trials – Open Forum Infectious Diseases

 


NIH Treatment Guideline Update: “there are insufficient data to recommend either for or against the use of tocilizumab or sarilumab for the treatment of COVID-19”

5 Feb, 2021 | 01:44h | UTC

The COVID-19 Treatment Guidelines Panel’s Statement on the Use of Tocilizumab (and Other Interleukin-6 Inhibitors) for the Treatment of COVID-19 – National Institutes of Health

 


Dialysis patients have 4-fold greater risk of dying from COVID-19

5 Feb, 2021 | 01:39h | UTC

News Release: Dialysis patients have 4-fold greater risk of dying from COVID-19 – Canadian Medical Association Journal

Original Study: COVID-19 in patients undergoing long-term dialysis in Ontario – Canadian Medical Association Journal

 


Randomized trial: Safety and efficacy of long-term mild hypothermia for severe traumatic brain injury with refractory intracranial hypertension

4 Feb, 2021 | 01:18h | UTC

Safety and efficacy of long-term mild hypothermia for severe traumatic brain injury with refractory intracranial hypertension (LTH-1): A multicenter randomized controlled trial – EClinicalMedicine

 

Commentary on Twitter

 


German 2021 guideline update on acute therapy and management of anaphylaxis

4 Feb, 2021 | 01:17h | UTC

Guideline (S2k) on acute therapy and management of anaphylaxis: 2021 update – Allergo Journal International

 


RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19

4 Feb, 2021 | 01:39h | UTC

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – The Lancet

Invited Commentary: Azithromycin, RECOVERY, and the power of large, simple trials – The Lancet

 


[Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials

1 Feb, 2021 | 01:58h | UTC

Full-Dose Heparin Best for Moderate COVID-19 Regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials – MedPage Today (free registration required)

Trial results: ATTACC, ACTIV-4a & REMAP-CAP multiplatform RCT Results of interim analysis – ATTACC Trial

News release: Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients – National Institutes of Health

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.